Lithium News and Research

RSS

Point of care hemoglobin analyzer launched by EKF Diagnostics at Medica 2014

EKF, has introduced the DiaSpect TM POC hemoglobin analyzer at Medica.

From EKF Diagnostics 17 Nov 2014

People treated with lithium drug are at risk of acute kidney damage

People with bipolar disorder who are being treated with the drug lithium are at risk of acute kidney damage and need careful monitoring, according to new research from the University of East Anglia (UEA) and Norfolk and Suffolk NHS Foundation Trust.

14 Nov 2014

Experts review advances in understanding, treatment of bipolar disorder

Several lines of research have opened exciting new frontiers in scientific understanding and clinical management of bipolar disorder. Recent advances in bipolar disease research are described in this month's special issue of Harvard Review of Psychiatry.

11 Nov 2014

Novel therapeutic approaches to improve thyroid cancer outcomes

Novel therapeutic approaches to improve outcomes in thyroid cancer, for example using targeted delivery of cytotoxic drugs to tumor cells, will be among the topics featured in oral and poster presentations delivered at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California.

30 Oct 2014

$Insulin resistance linked to treatment-refractory bipolar disorder$

Insulin resistance linked to treatment-refractory bipolar disorder

Patients with bipolar disorder who are insulin resistant are likely to also be refractory to mood-stabilising treatment, report researchers.

22 Oct 2014

Pointers for boosting prophylactic bipolar treatment reported

Patients with newly diagnosed bipolar disorder who have not previously used psychiatric drugs or have short hospital admissions should be targeted for prophylactic treatment, say researchers.

8 Oct 2014

Dendritic spine density also reduced in bipolar disorder

Patients with bipolar disorder have significant dendritic spine loss in the dorsolateral prefrontal cortex, postmortem findings show.

2 Oct 2014

Brain & Behavior Research Foundation to honor 8 scientists for achievements in psychiatric research

The Brain & Behavior Research Foundation will honor eight scientists with its 2014 Outstanding Achievement Prizes for work delving into psychiatric disorders that affect one in four people. The awards, which celebrate the transformative power of neuroscience and psychiatric research to improve the lives of people with mental illness, will be presented at the Foundation's National Awards Dinner at the Pierre Hotel.

30 Sep 2014

NRL scientists develop novel one-step process to form oxide nanoparticles

Scientists at the U.S. Naval Research Laboratory Materials Science and Technology Division have developed a novel one-step process using, for the first time in these types of syntheses, potassium superoxide (KO2) to rapidly form oxide nanoparticles from simple salt solutions in water.

25 Sep 2014

Longer looks: Lithium in the water; controlling cancer; recovering from brain injury

There are many kinds of cancer, but treatments have typically combatted them in one way only: by attempting to destroy the cancerous cells. Surgery aims to remove the entire growth from the body; chemotherapy drugs are toxic to the cancer cells; radiation generates toxic molecules that break up the cancer cells' DNA and proteins, causing their demise.

19 Sep 2014

Benefits and risks of hatha yoga for people with bipolar disorder

Right now no one can say whether yoga provides clinical benefits to people with bipolar disorder, but in a new article in the Journal of Psychiatric Practice, researchers report survey responses they gathered from scores of people with the condition who practice yoga. What the collective testimony suggests is that yoga can be a substantial help, but it sometimes carries risks, too.

18 Sep 2014

Researchers open a kind of window into inner workings of lithium-ion battery

For the first time, researchers have been able to open a kind of window into the inner workings of a lithium-ion battery.

9 Sep 2014

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Silvergate Pharmaceuticals, Inc., focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved Epaned for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart failure and to reduce hospitalization for heart failure).

9 Sep 2014